Plain-English translation of NCT06964568 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called a , given as an infusion after standard radiation and chemotherapy treatment, can help people with advanced esophageal cancer live longer and healthier lives. The study compares two groups: one that receives the new medication for a year after radiation and chemotherapy, and one that receives only the radiation and chemotherapy. Researchers want to learn if this additional treatment works better than the standard approach alone.
Advanced esophageal cancer is a serious disease, and current treatments don't work well enough for many patients. This medication works by helping your immune system recognize and attack cancer cells, and researchers believe it may improve survival when given after radiation and chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will first receive standard radiation and chemotherapy treatment given concurrently over several weeks. Then, depending on which group you are randomly assigned to, you will either receive the new immune-boosting medication as an intravenous infusion (a needle in your vein) once every 3 weeks for one year, or you will enter a surveillance period where your doctors monitor your health without the additional medication. Throughout the trial, you will have regular visits with your medical team for check-ups and blood tests to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Fudan University
Enrollment target
~452 participants
Started
February 2025
Primary completion
February 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kuaile Zhao, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.